Chemistry products provider, Array Biopharma, cuts range for its proposed IPO

Array Biopharma, a provider of discovery chemistry products and services for new drugs, cut its price range from $10-$12 to $9-$11, according to an SEC filing. The firm's proposed market capitalization after the offering will now be approximately $214 million. Lead underwriter, Lehman Brothers, is expected to price this deal in November.